Open original FDA record ↗Recall record
- FDA identifier
- Z-1019-2026
- Company in FDA record
- Meridian Bioscience Inc
- FDA classification date
- Jan 5, 2026
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
The affected lots show a decline in performance over time, which may lead to false-negative results.
Source facts
- Action
- An "URGENT MEDICAL DEVICE CORRECTION" dated 12/1/25 was sent to customers. Required Actions: " Identify and segregate any remaining inventory of impacted product lots and suspend further use. " Destroy remaining inventory of impacted product lot in accordance with state, local, and/or federal regulations. o Contact Technical Service for replacement product. " Review previously obtained results from Revogene C. difficile listed Lots numbers. Any negative results obtained should be re-evaluated in conjunction with presented clinical findings to determine if retesting is required. " Complete and return the CONFIRMATION OF NOTIFICATION Form. Complete this form even if there is no remaining inventory. Actions to Be Taken By Meridian Bioscience, Inc.: Meridian Bioscience, Inc. will replace any unused inventory and provide support for any necessary retesting, including replacement test materials as needed. Contact Information: For any question regarding this notification please call Meridian Bioscience Technical Service at 1-800-343-3858, or email at FieldActionSupport@meridianbioscience.com.
- Initiated
- 2025-12-05
- Root cause
- Under Investigation by firm
- Distribution
- US Nationwide distribution and the OUS country of Italy.
- Recall number
- Z-1019-2026
- Recall status
- Open, Classified
- CDRH record ID
- 217467
- FDA classified
- 2026-01-05
- Recall event number
- 98038